Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PD-1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PD-1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed. |
View PD-1 Products |
| Gene Delivery | PD-1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Endotoxin Controlled. |
View PD-1 Products |
| Benchmark Ab | Anti-PD-1 (Sequence of Pembrolizumab/Nivolumab) Recombinant positive control for blocking assays. Sequence Verified. |
View PD-1 Products |
| Validator | PD-1 siRNA Set For knockdown verification and specificity profiling. Sequence Verified. |
View PD-1 Products |
| Related Target A | PD-L1 (CD274) Primary natural ligand for competitive binding assays. |
View PD-L1 Products |
| Related Target B | LAG-3 (CD223) Synergistic immune checkpoint for bispecific (PD-1/LAG-3) development. Co-expression with PD-1 defines exhausted T-cell states. |
View LAG-3 Products |
| Related Target C | CTLA-4 (CD152) Orthogonal checkpoint pathway for dual-blockade rational design and bispecific strategies. |
View CTLA-4 Products |
| Related Target D | TIM-3 (HAVCR2) Emerging exhaustion marker for triple-combination checkpoint therapies. |
View TIM-3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Translation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity and theoretical MW confirmation. Sequence verified by Mass Spec. |
| Native Glycosylation Requirement | HEK293 mammalian expression system strictly utilized to preserve complex post-translational modifications. |
| Lack of Robust Controls | Clinical Benchmark Antibodies (Biosimilar sequences) included for direct head-to-head SPR and Flow Cytometry. |
| Off-Target False Positives | Valid sequence-verified siRNA included for precise in vitro specificity checks. |
| Subfamily off-target screening (CD28/CTLA-4/ICOS/BTLA) | Homolog panel proteins strictly verified by mass spec; high-purity ECD-Fc fusions enable clean selectivity assays. |
| PD-L1/PD-L2 binding competition assays | High-purity PD-L1 and PD-L2 proteins available for heterodimeric competition studies. |
| Fc Effector Function Liability Screening | Low-Endotoxin (<0.1 EU/ug) Benchmark Antibodies for FcγR binding assays. |
| High-concentration Sub-Q formulation stability | High-purity PD-1 antigen with Theoretical MW consistency; supports viscosity and aggregation screening at >100 mg/mL antibody concentrations. |
Live PD-1/CD279/PDCD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PD-1 therapeutics is intensifying, with major players shifting focus from traditional monospecific mAbs to next-generation bispecific antibodies (e.g., PD-1/VEGF, PD-1/CTLA-4) and subcutaneous high-concentration formulations. As first-generation anti-PD-1 therapies dominate frontline solid tumor indications, the next wave of R&D is aggressively targeting resistance bypass mechanisms, combination therapies, predictive biomarker-driven patient selection, and differentiated Fc-engineered formats to improve durability while minimizing immune-related adverse events. The emergence of resistance (primary, adaptive, acquired) demands sophisticated cross-target assay panels for LAG-3, TIM-3, and TIGIT inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Sub-Q) | Merck, BMS, Roche, Regeneron | Solid Tumors (NSCLC, Melanoma, HNSCC) | High-Concentration Stability (Need strictly endotoxin-controlled ECD-Fc); Receptor occupancy & blocking assay. |
| Bispecific (PD-1/VEGF) | Akeso, Summit, Innovent | NSCLC, HCC, Refractory Solid Tumors | Heterodimer Validation & dual-target engagement (Need cross-reactive species orthologs and PD-1/PD-L1 pair). |
| Bispecific (PD-1/CTLA-4) | Agenus, MacroGenics, Akeso (康方生物) | Solid Tumors | Heterodimer validation (Need Cross-reactive Abs, Dual-antigen bridging assays). |
| Fc-Engineered / Effector-null mAbs | Bristol Myers Squibb, AstraZeneca | Autoimmune / Oncology cross-over | Fc-gammaR binding differential assay (Need low-endotoxin benchmark antibodies; PD-1 expressing cell lines). |
| ADC (Antibody-Drug Conjugate) | Various early-stage biotechs | Targeted Checkpoint Degradation | Internalization Assay (Need Lentivirus cell lines & recombinant proteins). |
| Small Molecule Inhibitor | Incyte, Aurigene | Oral IO Therapies | Selectivity Assay (Need Sequence Verified Wild-Type and Mutant Proteins). |
| Cell Therapy (PD-1 KO) | CRISPR Therapeutics, Caribou | Hematologic Malignancies | Knockout validation (Need PD-1 ORF Lentivirus for genetic rescue experiments). |
Note: All products are designed with rational quality attributes: Sequence Verified by Mass Spectrometry, HEK293 Expressed for Native Mammalian Glycosylation, Endotoxin <1 EU/ug (LAL method), and Theoretical MW confirmed by SDS-PAGE.